NOURA JEGHALEF

Dr. NOURA JEGHALEF

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2021 in Life
Verified
Journal Article
Open access
PDF file
Vanessa Sánchez-MartínezVanessa Sánchez-Martínez
Vanessa Sánchez-Martínez
CBCristina Buigues
Cristina Buigues
RNRut Navarro-Martínez
Rut Navarro-Martínez
LGLaura Garcia-Villodre
Laura Garcia-Villodre
NJNOURA JEGHALEF
NOURA JEGHALEF
Omar CauliOmar Cauli
Omar Cauli
The relationship between cognitive decline and androgen deprivation therapy (ADT) under luteinizing hormone-releasing hormone (LHRH) analogues is unclear, and there is a scarcity of longitudinal studies considering the interaction between cognition, depressive symptoms and sleep quality in men with prostate cancer (PCa) treated with ADT. This study aimed to determine if there were differences in the scores obtained in cognitive assessment, depressive symptoms, and sleep quality after one year of ADT and determine the interrelations between sleep, mood, and cognitive status. A prospective longitudinal observational study was designed, in which a cohort of men (mean age was 70.8 years) newly treated with androgen-deprivation therapy was assessed in the first six months of treatment and 12 months later. Analysis of cognitive function by the Mini-Mental State Examination (MMSE) scores indicated a significant (p < 0.05) increase after one year of treatment and by the Brief Scale for Cognitive Evaluation (BCog) scores indicated no changes in the scores before and after one year of treatment. Analysis of depressive symptoms with the Geriatric Depression Scale and sleep quality with the Athens Insomnia Scale (AIS) scores showed significant (p < 0.05) changes after one year of treatment with ADT, with men describing more depressive symptoms and more sleep disturbances. No statistically significant differences were found in the cognitive performance between men with impaired sleep or depression results and those without them. Our study showed no clinical evidence of the relationship between ADT under luteinizing hormone-releasing hormone (LHRH) analogues and cognitive deterioration in 1-year follow-up, but there are impairments in the sleep quality in men with PCa undergoing ADT and an increase in depressive symptoms which has important implications for clinicians as they would impair quality of life and adherence to treatment.

25 July 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
JTJan Trallero
Jan Trallero
ASArantza Sanvisens
Arantza Sanvisens
FVFernando Almela Vich
Fernando Almela Vich
NJNOURA JEGHALEF
NOURA JEGHALEF
ILIsabel Saez Lloret
Isabel Saez Lloret
Rafael Marcos-GrageraRafael Marcos-Gragera
Rafael Marcos-Gragera
Background: Hematological neoplasms (HNs) are the first and most common childhood cancers globally. Currently, there is a lack of updated population-based data on the incidence of these cancers in the Spanish pediatric population. This study aimed to describe the incidence and incidence trends of HNs in children (0–14 years) in Spain using data from the Spanish Network of Cancer Registries and to compare the results with other southern European countries.Methods: Data were extracted from 15 Spanish population-based cancer registries between 1983 and 2018. Cases were coded according to the International Classification of Diseases for Oncology, third edition, first revision, and grouped according to the International Classification of Childhood Cancer, third edition. Crude rates (CRs), age-specific rates, and age-standardized incidence rates using the 2013 European population (ASRE) were calculated and expressed as cases per 1,000,000 child-years. Incidence trends and annual percentage changes (APCs) were estimated.Results: A total of 4,747 HNs were recorded (59.5% boys). Age distribution [n (%)] was as follows: <1 year, 266 (5.6%); 1–4 years, 1,726 (36.4%); 5–9 years, 1,442 (30.4%); and 10–14 years, 1,313 (27.6%). Leukemias were the most common group, with a CR and an ASRE of 44.0 (95%CI: 42.5; 45.5) and 44.1 (95%CI: 42.6; 45.7), respectively. The CR and ASRE of lymphomas were 20.1 (95%CI: 19.1; 21.1) and 20.0 (95%CI: 19.0; 21.1), respectively. The comparable incidence rates between our results and those of other southern European countries were similar for lymphomas, while some differences were observed for leukemias. From 1988 to 2016, the trend in leukemia incidence was stable for both sexes, with an APC of 0.0 (95%CI: −0.5; 0.7), whereas a constant overall increase was observed for lymphoma in both sexes, with an APC of 1.0 (95%CI: 0.4; 1.6).Conclusion: Leukemias are the most common HNs in children, and their incidence has remained stable since 1988, whereas the incidence of lymphomas has increased every year. Lymphoma incidence is like that of other southern European countries, while leukemia incidence is similar only to that of southwestern European countries. Collaborative cancer registry projects allow for assessing epidemiological indicators for cancers such as HNs, which helps health authorities and clinicians provide more knowledge about these malignancies.

28 July 2025 in European Journal of Cancer
Verified
Journal Article
Open access
MMMartin McCabe
Martin McCabe
SRSilvia Rossi
Silvia Rossi
FCFrancesco Cerza
Francesco Cerza
Maura MassiminoMaura Massimino
Maura Massimino
FGFrancesca Gianno
Francesca Gianno
ATAnnalisa Trama
Annalisa Trama
Data on the incidence and survival of central nervous system (CNS) tumour entities in adolescents and young adults (15-39 years at cancer diagnosis [AYA]) are scarce. Our objective is to provide incidence, survival and survival trends of CNS tumours in European AYAs and compare with older and younger patients with the same tumours. We used the EUROCARE-6 database, calculating incidence rates (IR) per 1000,000 individuals/year in the European population (years of diagnosis: 2006-2013), 1-,2-,3-,4- and 5-year relative survival (RS), 5-year RS conditional to surviving the first year after diagnosis, for the follow-up period 2010-2014 (cases diagnosed in 2006-2013) and changes in survival in the years 2000-2013. The IR for CNS tumours was around 20 per 1000,000 in AYAs and children and increased with increasing age. In AYAs, adults (40-69 years), and elderly (70 + years), CNS tumours other than gliomas were very rare. AYAs had better survival than children for gliomas, ependymomas and medulloblastoma and better survival than adults and elderly for all tumours examined. There was a slight improvement in survival of CNS tumours across age groups in Europe throughout 2000-2013. Differences in survival between children and AYAs may be due to differences in biology and treatment. The improvement in survival may be due to advances in neuroimaging and neurosurgical techniques, centralization of neurosurgical and neurooncology expertise, and multidisciplinary management. Our findings are relevant for informing patients and clinicians about survival in AYA CNS tumours that are rarely included in clinical trials.

21 May 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
JGJaume Galceran
Jaume Galceran
AAAlberto Ameijide
Alberto Ameijide
NJNOURA JEGHALEF
NOURA JEGHALEF
AGANTONIA SÁNCHEZ GIL
ANTONIA SÁNCHEZ GIL
MGMarcela Guevara
Marcela Guevara
MCMarià Carulla
Marià Carulla
Background: Childhood cancer survivors are more likely to develop cancer in adulthood than people of similar age in the general population. In Spain, there are no popula-tion-based studies on the risk of developing second cancers in people diagnosed with childhood cancer. The main objective of this study was to present recent survival rates fol-lowing a childhood cancer diagnosis in Spain and to investigate the risk of second malig-nant neoplasms (SMNs) in people diagnosed with childhood cancer between 1990 and 2009. Methods: This population-based registry study, devised by the Spanish Network of Cancer Registries (REDECAN), collected data on all malignancies and non-malignant neoplasms of the CNS diagnosed before age 15 years in populations covered by 12 cancer registries of Spain. Age-standardised incidence rates (ASIRw) for the period 2015–19 were calculated per million childhood-years. Five-year and 10-year age-adjusted observed sur-vival rates, for the periods 1990-1999 and 2000–2009 were estimated. The risk of develop-ing SMNs was calculated using standardized incidence ratio (SIR), excess absolute risk (EAR). Age-specific incidence rates of SMN were also calculated. Results: During the pe-riod 2015-2019, the ASIRw was 181.3 per million child-years. The 10-year childhood sur-vival rate for both sexes combined increased from 71.3% to 75.5% between the 1990s and the 2000s. The relative risk of a SMN in people with a first childhood cancer diagnosed between 1990 and 2009 was 5.67 at 20 years after the diagnosis of the first cancer. Conclu-sion: In the 2000s, the 10-year survival rate for childhood cancer in Spain was around 75%, but survivors faced a high risk of developing a second cancer for at least 20 years af-ter their initial diagnosis. Efforts to reduce treatment-related toxicity are essential to miti-gate this long-term risk without compromising survival outcomes.

18 June 2026 in Cancers
Verified
Journal Article
Open access
PDF file
JGJaume Galceran
Jaume Galceran
AAAlberto Ameijide
Alberto Ameijide
NJNOURA JEGHALEF
NOURA JEGHALEF
AGANTONIA SÁNCHEZ GIL
ANTONIA SÁNCHEZ GIL
MGMarcela Guevara
Marcela Guevara
O(On Behalf Of The Spanish Network Of Cancer Registries (Redecan)
On Behalf Of The Spanish Network Of Cancer Registries (Redecan)
Background: Childhood cancer survivors have a higher risk of developing malignancies later in life compared with individuals of similar age in the general population. In Spain, population-based evidence on second malignant neoplasms (SMNs) is limited. This study aimed to estimate survival following childhood cancer diagnosis and to assess the risk of SMNs in Spain. Methods: This population-based registry study used data from 12 cancer registries within the Spanish Network of Cancer Registries (REDECAN). All malignancies of sites and non-malignant central nervous system (CNS) tumors diagnosed before age 15 were included. Age-standardized incidence rates (ASIRw) for 2015–2019 were calculated. Five- and 10-year age-adjusted observed survival rates for 1990–1999 and 2000–2009 were estimated. SMN risk was assessed using standardized incidence ratios (SIRs) and excess absolute risks (EARs). Results: The ASIRw for 2015–2019 was 181.3 per million child-years. Ten-year survival increased from 71.3% in 1990–1999 to 75.5% in 2000–2009. The overall risk of developing an SMN was significantly elevated (SIR = 5.67) at 20 years. Conclusions: Although survival for childhood cancer in Spain was around 75% in 2000–2009, childhood cancer survivors remain at substantially increased risk of SMNs for at least two decades. Efforts to reduce treatment-related toxicity while maintaining survival gains are essential.

6 November 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
CMCarmen Martos
Carmen Martos
LGLaura Garcia-Villodre
Laura Garcia-Villodre
LBLAIA BARRACHINA-BONET
LAIA BARRACHINA-BONET
PLParamo-Rodriguez Lucía
Paramo-Rodriguez Lucía
BABerta Arribas
Berta Arribas
CCClara Cavero-Carbonell
Clara Cavero-Carbonell
Despite advances in treatment, childhood cancer survivors continue to experience substantial comorbidities stemming from chronic health conditions and face an elevated risk of premature mortality compared to the general population